Indoco Remedies shares are currently trading at ₹227.75, representing a 0.77% increase from the previous closing price of ₹226.00 on the BSE. The stock opened at ₹225, showing positive momentum following the company's regulatory milestone. This upward movement reflects investor confidence in the company's enhanced export capabilities and regulatory compliance achievements.
Indoco Remedies has announced that the Malta Medicines Authority has granted EU GMP certification to the company's manufacturing facility. According to reports from Business Standard, the certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive. This development is crucial for the pharmaceutical company, which reported a US$175 million turnover, and is expected to enhance the Baddi facility's credibility and position Indoco Remedies to secure new export orders from European nations.
The certification follows a comprehensive inspection conducted by the Malta Medicines Authority from 29 January 2026 to 03 February 2026. As reported by Business Standard, the inspection covered the company's manufacturing facility for solid oral dosage form (Unit I) located at Baddi. The facility has now successfully met all regulatory requirements for EU GMP compliance, aligning more closely with major Indian pharmaceutical peers such as Cipla, Sun Pharma, and Lupin who also operate EU GMP-certified manufacturing sites to serve the European market.
Commenting on the development, Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated that "This approval from the Malta Medicine Authority further reflects Indoco's strong commitment to quality, compliance and adherence to global regulatory standards. We are focused on maintaining the highest quality standards while catering to our customers in India and globally." Obtaining EU GMP certification is essential for pharmaceutical companies looking to export to EU countries, signaling adherence to the highest international benchmarks for drug manufacturing.
The Baddi plant plays a central role in Indoco's production of solid oral dosage forms, a key business segment, and this certification supports the company's strategy to expand its international presence. The European generics market is highly competitive, demanding ongoing innovation and cost management. Maintaining strict adherence to EU GMP standards will be crucial to preserve the certification and avoid future compliance issues. Investors will be looking for actual growth in EU export orders, new product launches in Europe facilitated by the Baddi facility, further certifications for other Indoco units, and management's commentary on strategic expansion plans stemming from this approval.
